Rising cancer cases, funding initiatives by governments, and advanced treatment techniques are elevating the PARP inhibitors market. Cancer Australia’s “Supporting people with Cancer” grant initiative provides organization with grants up to $120,000 to support projects aimed at reducing the cancer burden. Effective partnerships between organizations to improve coordination, accessibility, and development of quality cancer support networks are also responsible for the market growth.